Abstract
Pancreatic cancer is the eighth most common cancer and one of the most deadly. Eighty-five percent of pancreatic cancers are classified as pancreatic ductal adenocarcinoma (PDAC). Challenges in treating PDACs include advanced stage at the time of diagnosis and chemoresistance. Patient-derived xenograft (PDX) models of PDAC have been established to study tumor biology and as a platform to test new therapeutic agents. PDX engraftment has the potential use as a predictor of disease recurrence in patients who undergo curative resection for PDAC, who represent less than 20% of the patient population affected by this malignancy. Establishing a PDX tissue bank will lead to better understanding of the biology of pancreatic cancer from the study of genotyping, proteomics, and molecular tumor-stroma interactions and will support establishing preclinical models for drug testing and biomarker discovery. The impact of PDX models on patient care is increasing as a result of their use in the discovery of new therapies and prognostic molecular biomarkers.
| Original language | English (US) |
|---|---|
| Title of host publication | Patient Derived Tumor Xenograft Models |
| Subtitle of host publication | Promise, Potential and Practice |
| Publisher | Elsevier Inc. |
| Pages | 229-241 |
| Number of pages | 13 |
| ISBN (Electronic) | 9780128040614 |
| ISBN (Print) | 9780128040102 |
| DOIs | |
| State | Published - 2017 |
Keywords
- PDAC
- PDOX
- PDX
- Pancreatic cancer
- Pancreatic cancer mouse model
- Pancreatic ductal adenocarcinoma
- Pancreatic tumor
- Patient-derived orthotopic xenograft
- Patient-derived xenograft
- Tumor xenograft
ASJC Scopus subject areas
- General Medicine